NCT01923233View on ClinicalTrials.gov

In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

AlloStim

allogeneic Th1 memory cell with CD3/CD28-coated microbeads attached.

Trial Locations (1)

Unknown

Hadassah-Hebrew University Medical Center, Jerusalem

Sponsors
All Listed Sponsors
lead

Mirror Biologics, Inc.

INDUSTRY

NCT01923233 - In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer | Biotech Hunter | Biotech Hunter